Search clinical trials for: Fluorescein ALA

Total 256563 results

Biofrontera Bioscience GmbH
Accovion GmbH

Completed

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Actinic Keratosis
M.D. Anderson Cancer Center

Completed

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

Leukemia

United States
National Institute on Aging (NIA)

Completed

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

Acute ST Elevation Myocardial Infarction

United States
Janssen-Ortho Inc., Canada

Withdrawn

A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

Anemia | Blood Transfusion | Orthopedic Surgery
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia
Stanford University
National Institute on Aging (NIA)

Withdrawn

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

Anemia

United States
University Medical Center Groningen
Janssen-Cilag Ltd.; The Interuniversity Cardiology Institute of the Netherlands

Completed

Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction (HEBEIII)

Myocardial Infarction

Netherlands
Institut Universitari Dexeus

Completed

Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa

Infertility

Spain
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
University of South Florida
Ortho Biotech, Inc.

Terminated

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa (EPO)

Subarachnoid Hemorrhage

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Neoplasms | Anemia
Biofrontera Bioscience GmbH

Active, not recruiting

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Superficial Basal Cell Carcinoma

United States
Sandoz
Hexal AG

Completed

MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5 (MONITOR-CKD5)

Chronic Kidney Disease | End-stage Renal Disease | Anaemia

Austria, France, Germany, Italy, Poland, Romania, Slovenia, Spain, Switzerland, United Kingdom
David W. Roberts
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Fluorescence Guided Resection of Brain Tumors (FGR)

Brain Tumors

United States
Aqualung Therapeutics Corp.

Not yet recruiting

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

Acute Respiratory Distress Syndrome (ARDS)
University Eye Hospital, Freiburg
German Federal Ministry of Education and Research

Completed

Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial (TONE)

Optic Neuritis

Germany
Merck Sharp & Dohme LLC

Terminated

A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)

Anemia | Chronic Kidney Disease
European Organisation for Research and Treatment...
Charite University, Berlin, Germany; Trans Tasman Radiation Oncology Group; Groupe... and other collaborators

Terminated

Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer

Head and Neck Cancer

France, Belgium, Israel, United Kingdom, Australia, Spain, Germany, Switzerland, Hungary, Netherlands
Northwestern University
National Cancer Institute (NCI)

Completed

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

Fatigue | Anemia | Unspecified Adult Solid Tumor, Protocol Specific

United States
Washington University School of Medicine
National Institute of Neurological Disorders and Stroke (NINDS); PPD; Ortho Biotech...

Withdrawn

Epoetin Alfa for HIV-Associated Neuropathy Trial

HIV Infections | Neuropathy
Biofrontera Bioscience GmbH

Completed

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

Actinic Keratosis
MultiCare Health System Research Institute

Terminated

A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors

Glioma | Glioblastoma | Astrocytoma | Glioblastoma Multiforme | Malignant Glioma

United States
medac GmbH

Completed

Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid

Brain Cancer | Brain Tumors | Brain Tumor, Primary | Primary Brain Tumors | Cancer of Brain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Bintrafusp Alfa Program Rollover Study

Cancer | Lung Cancer

Korea, Republic of, Spain, Germany, Japan, Taiwan, China, Italy, United States, Belgium, Russian Federation, Turkey, Ukraine
Novo Nordisk A/S

Completed

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities (THIRd)

Haemophilia A

Italy
EMD Serono Research & Development Institute, Inc.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Terminated

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

United States, France, Belgium, Spain, Russian Federation, Italy
Novo Nordisk A/S

Completed

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Congenital Bleeding Disorder | Haemophilia A

Mexico
Novo Nordisk A/S

Terminated

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

Haemophilia A

Austria, Serbia, Bulgaria, United Kingdom, Germany, France, Turkey
Novo Nordisk A/S

Completed

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period (guardian 10)

Congenital Bleeding Disorder | Haemophilia A

India
Novo Nordisk A/S

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (guardian ™9)

Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
AstraZeneca
LOGEX Healthcare Analytics Amsterdam The Netherlands

Recruiting

Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya

Hemorrhage

Netherlands
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
Novo Nordisk A/S

Completed

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

Congenital Bleeding Disorder | Haemophilia A

Japan
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (guardian™ 5)

Congenital Bleeding Disorder | Haemophilia A

Italy, Sweden, Netherlands, Austria, Spain, United States, Switzerland, Germany, France, Hungary, Greece, Slovenia, Czechia, Slovakia, Poland
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects (guardian™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Japan, Denmark, Hungary, Israel, Turkey, Russian Federation, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

Congenital Bleeding Disorder | Haemophilia A

United Kingdom, Malaysia
Alnylam Pharmaceuticals

Completed

Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

Solid Tumors

United States, Spain
Biofrontera Bioscience GmbH

Completed

Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

Actinic Keratosis

Germany
Amgen

Completed

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Anemia | Non-Myeloid Malignancies
USDA Grand Forks Human Nutrition Research Center

Completed

Acute Effects of Fats on Satiety and Energy Needs

Obesity

United States
Constantinos Hadjipanayis
Massachusetts General Hospital

Completed

5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor

Malignant Gliomas

United States
Fundación GECP

Recruiting

Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES)

Mesothelioma; Lung

Spain
Alnylam Pharmaceuticals

Terminated

A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout

Gout

United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Uterine Cervical Neoplasms

Korea, Republic of, United States, France, Belgium, China, Argentina, Spain, Australia, Russian Federation, Brazil, Hungary, Japan
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Tel-Aviv Sourasky Medical Center

Unknown

The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors (5-ALA)

Central Nervous System Tumor, Pediatric

Israel
Alnylam Pharmaceuticals

Completed

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

Solid Tumors

United States, Spain
National Institute of Diabetes and Digestive and...

Completed

Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)

Diabetes Mellitus, Insulin-Dependent

United States
National Center for Research Resources (NCRR)
Juvenile Diabetes Research Foundation

Unknown

hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure

Islets of Langerhans Transplantation | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Experimental | Transplantation, Homologous

United States
Groupe Francophone des Myelodysplasies

Recruiting

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)

Myelodysplastic Syndromes

France

Search clinical trials for: Fluorescein ALA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations